ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-3862ometendo-3862Research ArticleСтатьиArticlesСостояние углеводного и липидного обмена у пациентов с ожирением и сахарным диабетом 2 типа после билиопанкреатического шунтированияStatus of carbohydrate and lipid metabolism in obese patients with type 2 diabetes mellitus after biliopancreatic diversion surgeryErshovaE V

научный сотрудник отделения терапии с группой ожирения ФГБУ Эндокринологический научный центр Минздрава РФ

yu99pol06@rambler.ruYashkovYu I

д.м.н., профессор, хирург ЗАО Центр эндохирургии и литотрипсии, Президент Европейской федерации хирургии ожирения и метаболических нарушений (IFSO-EU Chapter) в 2012–2014 гг.

yashkov@celt.ru201330102013103№3 (2013)2836Copyright © Ershova E.V., Yashkov Y.I., 20132013Ershova E.V., Yashkov Y.I.Ershova E.V., Yashkov Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/3862

Обследовано 70 пациентов с ожирением и сахарным диабетом 2 типа до и на протяжении 5 лет после билиопанкреатического шунтирования: через 3 месяца после операции у больных отмечено существенное улучшение состояния углеводного и липидного обмена, которое наряду со сниженной массой тела сохранялось на протяжении всего срока наблюдения.

We examined 70 patients with obesity and diabetes mellitus type 2 before and within 5 years after BPD: these patients showed a significant improvement in the status of carbohydrate and lipid metabolism within 3 months after surgery. This improvement has remained stable along with the reduced body weight during the whole observation period of up to 5 years.

ReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом (под рук. Дедова И.И. и соавт., 5-й выпуск). Сахарный диабет. 2011; (3 прил. 1): 4-72.Алгоритмы специализированной медицинской помощи больным сахарным диабетом (под рук. Дедова И.И. и соавт., 5-й выпуск). Сахарный диабет. 2011; (3 прил. 1): 4-72.Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет. 2010; 3(48): 6–13.Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет. 2010; 3(48): 6–13.Яшков Ю.И., Никольский А.В., Бекузаров Д.К., Ершова Е.В., Огнева Н.А. Cемилетний опыт применения операции билиопанкреатического отведения в модификации Hess–Marceau в лечении морбидного ожирения и сахарного диабета 2 типа. Ожирение и метаболизм. 2012; 2: 43–48.Яшков Ю.И., Никольский А.В., Бекузаров Д.К., Ершова Е.В., Огнева Н.А. Cемилетний опыт применения операции билиопанкреатического отведения в модификации Hess–Marceau в лечении морбидного ожирения и сахарного диабета 2 типа. Ожирение и метаболизм. 2012; 2: 43–48.Andreelli F., Amouyal C., Magnan C. et al. What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab. 2009; 35(6 Pt 2): 499–507.Andreelli F., Amouyal C., Magnan C. et al. What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab. 2009; 35(6 Pt 2): 499–507.Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724–37.Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724–37.Buchwald H., Estok R., Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122: 249–61.Buchwald H., Estok R., Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122: 249–61.Сummings D., Overduin J., Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004; 89: 2608–15.Сummings D., Overduin J., Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004; 89: 2608–15.Gumbs A., Modlin I., Ballantyne G. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005; 15(4): 462–73.Gumbs A., Modlin I., Ballantyne G. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005; 15(4): 462–73.Heber D., Greenway F., Kaplan L. et al. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2010; 95(11): 4823–43.Heber D., Greenway F., Kaplan L. et al. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2010; 95(11): 4823–43.Hess D.S., Hess D.W. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998; 8(3): 267-82.Hess D.S., Hess D.W. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998; 8(3): 267-82.Hill J., Wyatt H., Reed G. et al. Obesity and environment: where do we go from here? Science. 2003; 299: 853–55.Hill J., Wyatt H., Reed G. et al. Obesity and environment: where do we go from here? Science. 2003; 299: 853–55.IDF taskforce on the epidemiology and prevention, 2011.IDF taskforce on the epidemiology and prevention, 2011.Laferrere B., Heshka S., Wang K. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30: 1709–16.Laferrere B., Heshka S., Wang K. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30: 1709–16.Marceau P., Biron S., Bourque R. et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg. 1993; 3: 29–35.Marceau P., Biron S., Bourque R. et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg. 1993; 3: 29–35.Meneghini L. Impact of bariatric surgery on type 2 diabetes. Cell Biochem Biophys. 2007; 48: 97–102.Meneghini L. Impact of bariatric surgery on type 2 diabetes. Cell Biochem Biophys. 2007; 48: 97–102.Mingrone G., Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009; 35(6 Pt 2): 518–23.Mingrone G., Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009; 35(6 Pt 2): 518–23.Pories W., Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis. 2009; 5(2): 285–88.Pories W., Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis. 2009; 5(2): 285–88.Pories W., MacDonald K., Flickinger E. et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992; 215: 633–42.Pories W., MacDonald K., Flickinger E. et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992; 215: 633–42.Pories W., Swanson M., MacDonald K. et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg. 1995; 222: 339–52.Pories W., Swanson M., MacDonald K. et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg. 1995; 222: 339–52.Powers P. Conservative treatment for morbid obesity. In: Deitel M. Surgery for the morbidly obese patient. Philadelphia – London 1989; 27–37.Powers P. Conservative treatment for morbid obesity. In: Deitel M. Surgery for the morbidly obese patient. Philadelphia – London 1989; 27–37.Powers P. Treatment of obesity: drugs and surgery. In: Powers P.S. Obesity: the regulation of weight. Baltimore: Williams & Willkins, 1980; 325–38.Powers P. Treatment of obesity: drugs and surgery. In: Powers P.S. Obesity: the regulation of weight. Baltimore: Williams & Willkins, 1980; 325–38.le Roux C., Welbourn R., Werling M. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery. 2007; 246(5): 780–85.le Roux C., Welbourn R., Werling M. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery. 2007; 246(5): 780–85.Rubino F., Gagner M. Potencial of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002; 236: 554–59.Rubino F., Gagner M. Potencial of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002; 236: 554–59.Salinari S., Bertuzzi A., Asnaghi S. et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009; 32: 375–80.Salinari S., Bertuzzi A., Asnaghi S. et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009; 32: 375–80.Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291: 335–42.Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291: 335–42.Scopinaro N., Papadia F., Camerini G. et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg. 2008; 18: 1035–38.Scopinaro N., Papadia F., Camerini G. et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg. 2008; 18: 1035–38.World Health Organization.Global Health Risks: mortality and burden of disease attributable to selected major risks (2009). http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html.World Health Organization.Global Health Risks: mortality and burden of disease attributable to selected major risks (2009). http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html.Zimmer P., Alberti K., Shaw G. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782–87.Zimmer P., Alberti K., Shaw G. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782–87.

The authors declare that there are no conflicts of interest present.